Breast Cancer Management during Coronavirus Disease 2019 Pandemic: A Literature Review

Andree Kurniawan¹,²,• Devina Adella Halim¹,• Angela Giselvania⁴,• Noorwati Sutandyo⁵,• Sonar Soni Panigoro⁶ Asri Adisasmita⁷ Ratna Djuwita Hatma⁷

¹Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia
²Clinical Epidemiology, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia
³Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia
⁴Department of Radiation Oncology, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine,Universitas Indonesia, Jakarta, Indonesia
⁵Hematology and Medical Oncology, Department of Internal Medicine, Dharmais Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
⁶Department of Surgical Oncology, Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
⁷Department of Epidemiology, Faculty of Public Health, Universitas Indonesia, Depok, Indonesia

Address for correspondence Andree Kurniawan, MD, FINASIM, Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Karawaci, Tangerang, Banten 15811, Indonesia (e-mail: andree.kurniawan@uph.edu).

Introduction Breast cancer is the most prevalent cancer found in women. The World Health Organization declared the coronavirus disease 2019 (COVID-19) as a public health emergency of international concern. Delaying treatment was associated with mortality. The aim is to evaluate breast cancer management during the pandemic.

Methods We searched articles evaluating the management of breast cancer in the midst of COVID-19 outbreak, by searching in PubMed, PubMed Central, and Oncology Society related websites. We only included articles discussing adult breast cancer management in COVID-19 era. The two reviewers screened the titles and abstracts.

Results Around 124 articles were found through the searching process. Eight observational trials, two review articles, six guidelines or recommendations, and one letter to the editor were included in final review. It was concluded that breast cancer posed a risk to contract COVID-19. Newly suspected breast cancer could be deferred for screening or diagnosis, except for special breast cancer cases with bleeding, invasive, and complicated tumors. The benefit of radiotherapy option in every case should be carefully weighed against the risk of infection. Oral chemotherapy and hormonal therapy drugs were preferred to be given than intravenous chemotherapy. The scheduled chemotherapy could be adjusted to reduce hospital visit. Each breast cancer patient is different, so they should be discussed in multidisciplinary team consisting of surgical, radiation, and medical oncologists, pathologist, radiologist, palliative care people, nurses, nutritionist, and others related to the field.

Conclusion The International Oncology Society has released recommendations for breast cancer during COVID-19 pandemic but there is still questionable-quality evidence.

Keywords
- breast neoplasms
- COVID-19
- drug therapy

Abstract

DOI https://doi.org/10.1055/s-0040-1722809
ISSN 2454-6798.
Introduction

Breast cancer is the most prevalent cancer found in women with an estimated number of new cases in the European community being 404,920, while its estimated age-adjusted annual incidence is 144.9/100,000. Worldwide, in 2018, the incidence of breast cancer in females was up to 2.1 million.\(^1\) In the same year in Asia, newly confirmed cases kept rising with an estimated increment of more than 900,000 cases, constituting 43.6% of the newly reported breast cancer cases worldwide. On the other hand, its breast cancer death comprised about half of worldwide mortality, reaching more than 300,000 deaths.\(^2\)

The World Health Organization declared the Coronavirus disease 2019 (COVID-19) as a public health emergency of international concern. The newly discovered disease is a challenge for health care professionals. The full impact of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) in our health systems is yet to come and will be prolonged. Global confirmed cases of COVID-19 had reached more than 48.5 million, with more than 1.2 million deaths, while Indonesia has reported 429,574 cases with 14,442 deaths, as of November 6, 2020.\(^3\)

Timing of surgery after neoadjuvant chemotherapy, especially in estrogen receptor positive (ER+)/human epidermal receptor 2 positive (HER2+) patients if delayed more than 8 weeks, would impact on decreased overall survival and disease-free survival.\(^4\) Another study found that delaying breast cancer treatment of even a single modality will impact on higher breast cancer-specific mortality and all-cause mortality.\(^5\)

There is still limited data to recommend care for breast cancer patients in the midst of COVID-19 outbreak, resulting in fear of delay in treatment and impact on the overall survival of patients. The aim of this study is to know the best recommendation for breast cancer care during COVID-19 outbreak.

Methods

Search Strategies

A comprehensive search of the literature was conducted by searching in PubMed and PubMed Central databases, and for guidelines or recommendation by international societies of surgical oncology, radiation oncology, and medical oncology, from January 2020 to April 2020, with keyword combinations of the medical subject headings (MeSH) on April 9, 2020. The keywords “breast neoplasm” AND “COVID-19” AND “management” were used in search engine. Management of adult breast cancer patients through surgery, chemotherapy, and radiotherapy (RT) were the inclusion criteria. Articles in non-English language were excluded. Firstly, we searched the titles and abstracts. Then, we evaluated the full text whether it discussed breast cancer care in COVID-19 times.

Results and Discussion

Literature Search

We discovered 124 articles through the literature search strategy. The reviewing process of literature based on systematic reviews and meta-analysis (e.g., PRISMA: preferred reporting items for systematic reviews and meta-analyses) can be seen in ►Fig. 1. The two reviewers (A.K. and D.A.H.) screened the title and abstracts for 124 articles. Finally, we only included articles mainly discussing breast cancer management in adults during COVID-19 pandemic. There were eight observational trials, two review articles, six guidelines or recommendations, and one letter to the editor. The diagram of search literature can be seen in ►Fig. 1.

Risk of COVID-19 Infection in Cancer Patients

From the longitudinal COVID-19 infection data in China reported by Liang et al.,\(^6\) the incidence of cancer in the COVID-19 population seems to be higher than in the overall Chinese population. Breast cancer was found in 3 of 18 cancer patients (two in remission and one no information). Cancer patients were older (63.1 vs 48.7 years) and smokers (22% vs 7%). At diagnosis of COVID-19, patients presented more frequently with tachypnea (47% vs 23%) and with a more severe computed tomography (CT) pattern of infection (94% vs 7%). Cancer groups are more likely to develop more severe illness or death (50% vs 16%; \(p = 0.0008\)), even worse in those undergoing active treatment (75% vs 43%).\(^6\) After adjusting for the variables age and smoking in cancer patients, the results showed an odds ratio (OR) for more severe complications (OR = 5.34; 95% confidence interval = 1.8–16.18; \(p = 0.00026\)). The risk seemed to be independent of cancer types.\(^7\)

What Oncologist Should Do?

Discussing the possible options for health care professionals on how to deal with patients with recent diagnoses/suspected breast cancer or with ongoing treatment within the recent COVID-19 pandemic context should be done in a multidisciplinary team (MDT) meeting. Several scenarios should be considered for breast cancer management according to the diverse pandemic scenarios in different countries.\(^8\)

Preparation

Test all patients planned to receive elective surgery and emergency surgery for COVID-19, like using rapid tests. The decision needs to comply with local test availability, and choosing the proper test needs to rely on proper timing to obtain valid test results.\(^8\)

Screening and Diagnosis

Breast cancer screening, with mammographic use, should be postponed until the outbreak is over. Symptomatic cases that need diagnostic procedure should be managed according to local availability. On the other hand, considering the burden
on clinical outcomes, regular evaluation should be performed in patients with unusual symptoms and signs.8

Initial breast cancer work-up should be conducted only in patients with node-positive breast cancer. Magnetic resonance imaging should only be done in COVID-19 negative patients due to the risk of device contamination. CT scan should be avoided whenever possible because the prioritization is for COVID-19 positive patient evaluation. Other imaging use, for instance echocardiography monitoring, was considered to be postponed if no cardiac symptoms and no previous reduction in ejection fraction were observed. Alternatively, troponin and brain natriuretic peptide laboratory checks from blood samples can be done.8

Outpatient consultation should be changed to telemedicine consultation. Appointments should be prioritized according to urgency using high, medium, and low-priority stratification.8 Further information about stratification can be retrieved from »Table 1.

Surgery

Ideally, team members must be reduced to lessen the possibility of contacts and allow for replacement in case of getting contracted. All booking procedures per day should be reduced, regarding the time needed to disinfect carefully. Most procedures should be technically contraindicated or need to be replaced.8

All decisions to proceed with the surgical procedure should be discussed in MDT meeting, which could be held through teleconference platform. The results should be further deliberated with the patient and should depend on their desire to take the final decision.

Before initiating invasive procedure, such as surgery, ideally all patients should be screened for COVID-19, although asymptomatic. When the presence of SARS-CoV2 is detected, the patients should be treated as COVID-19 patient first while the procedure and/or treatment can be resumed afterward.9

Fig. 1 PRISMA (preferred reporting items for systematic reviews and meta-analyses) search strategy.
Table 1 Stratification of outpatient consultation appointments into priority groups

<table>
<thead>
<tr>
<th>Priority</th>
<th>Interval until surgery</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urgency</td>
<td>&lt;2 weeks</td>
<td>• Patients with significant tumor burden not responding or progressing under PST</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pregnant patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Patients with complicated locally advanced tumor</td>
</tr>
</tbody>
</table>
| High priority| 2–4 weeks              | • Patients with early isolated locoregional recurrence (within 48 months from pri-
|              |                        | mary treatment)                                                                  |
|              |                        | • High-risk patients with contraindications to PST, if younger than 40 years or   |
|              |                        | node-positive, or with disease showing biological features of aggressiveness     |
| Medium priority| 4–8 weeks            | • Patients treated with PST (ideally at a maximum of 4–6 weeks after treatment   |
|              |                        | completion)                                                                      |
|              |                        | • Premenopausal patients with small (<2 cm) node-negative tumors                  |
| Low priority | >8 weeks               | • Ductal carcinoma in situ (However, high-grade ER-negative or very extensive DCIS |
|              |                        | and/or with a palpable lump or extensive microcalcifications might fall into the  |
|              |                        | intermediate priority category, based on individual consideration of each case)   |
|              |                        | • Postmenopausal patients with luminal A-like cancer; in these women, primary    |
|              |                        | endocrine therapy could be initiated and surgery could be postponed              |

Abbreviations: DCIS, ductal carcinoma in situ; ER, estrogen receptor; PST, primary systemic therapy.

Recommendation for Surgery in Breast Cancer
In recent weeks there were recommendations from the cancer working groups and country experiences in caring breast cancer patients in the COVID-19 era. Further details of surgical therapy priority in breast cancer have been provided in Table 2.

Radiotherapy
The role of RT in breast cancer causes significant impact on reducing locoregional recurrences and improving survival. However, in particular patients it might have no survival implications, for instance in ductal carcinoma in situ cases. The use of breast RT has to be thoughtfully evaluated in terms of its risk toward infection, in the middle of the pandemic.

Recommendations for RT for breast cancer in the COVID-19 pandemic include the changes in framework for patient care, such as use of remote visits/teleconsultations, patient prioritization, method of radiation, avoidance, delay or omission of RT, and the use of hypofractionation techniques.

Teleconsultations
Teleconsultations, using simple call or video calls, should be implemented to replace outpatient visit when possible. Telehealth technology can also be used upon availability, depending on local institutional resources and legal aspects. For clinic patients or those who are coming for their RT sessions, special strategy should be arranged. Patients should come only at their time of appointment and should spend the waiting time elsewhere until their scheduled time. Visitor numbers should be cut down to allow physical distancing in the waiting room. Patients should not be allowed to bring more than one companion. Laboratory testing should be performed with minimal contact to staff or other patients, and to avoid a busy hospital, possibly with a drive through system. Posttreatment routines, like tumor marker testing, can safely be postponed for up to 3 months.

Patient Prioritization
Under extreme circumstances, it is essential to make priority setting for patients who might be given RT for their survival benefit. Some tiers of elevated priority have been prepared based on available evidence and clinical judgment. This priority setting should be considered by the physician regarding the patient age, comorbidities, risk of exposure, and benefit prediction of RT.

Breathing Control
Active breathing control technique in breast RT is not recommended during the COVID-19 pandemic, since it may increase the risk of aerosol contamination. Additionally, consideration should be taken to minimize the use of device requiring decontamination. To reduce cardiac toxicities with no supplementary equipment and the risk of infection, deep inspiratory breath-hold techniques with voluntary breath hold might support.

Omission and Delay of Radiotherapy
Breast RT can be considered to be omitted in certain settings when the effect on survival is not very significant, such as in patients with noninvasive disease or older patients with low-risk disease who have minimal survival benefit from breast RT and much greater risk of mortality from COVID-19.}

Experts in several countries in the world discussed and made several recommendations for RT in breast cancer patients...
during COVID-19 pandemic. RT should be omitted for patients aged 65 years and older (or with relevant comorbidities in younger age) with invasive breast cancer that are up to 30 mm with clear margins, grades 1 to 2, ER+, HER2-negative, and node negative planning for treatment with endocrine therapy.

**Hypofractionation**
Adjuvant breast RT has been established as part of standard treatment with normal fractionated regimens of 50 Gy in 25 fractions daily over 5 weeks with or without a boost of 10–16 Gy in 5 to 8 fractions. Hypofractionation is possible in breast RT with strong supporting data. In the COVID-19 pandemic era, it is recommended to use hypofractionation scheme for all breast/chest wall and nodal RT, such as 40 Gy in 15 fractions over 3 weeks.14 Extreme hypofractionation scheme can be considered for patients with node-negative tumors that do not require a boost, as in hypofractionated breast RT for 1-week versus 3-week (FAST Forward) trial, with options including 28 to 30 Gy in 5 fractions weekly over 5 weeks or 26 Gy in 5 fractions daily over 1 week, respectively.14

In order to reduce the number of fractions and/or complexity of treatment, a boost in breast RT should be considered to be omitted whenever possible, unless in those with significant risk for local relapse, that is, 40 years old and under, or over 40 years with significant risk factors for local relapse. Nodal RT can be omitted in postmenopausal women requiring whole breast RT following sentinel lymph node biopsy and primary surgery for T1, ER+, HER2-negative, and G1 to 2 tumors with 1 to 2 macro metastases.15–17 Further indications of omitting RT treatment are provided in Table 4.

### Table 2 Priorities for breast cancer: surgical oncology10

<table>
<thead>
<tr>
<th>Priority</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| High     | • Breast cancer surgery complication with bleeding or indication to incision and drainage of a breast abscess and/or hematoma  
• Complications of reconstructing surgery, for instance, ischemia  
• Surgery in patients who have completed neoadjuvant chemotherapy-based treatment (or cases with progression of disease during neoadjuvant treatment)  
• Surgery in patients with invasive cancer after discussed in MDT  
• Breast cancer surgery during pregnancy (MDT decision should be according to the stage and biology) |
| Medium   | • Excision of malignant recurrence (depending on phenotype and extent)  
• Clinically low-risk primary breast cancer (e.g., stage I/II ER-positive/PR-positive/HER2-negative, low grade/low proliferative index tumors); MDT to decide on starting neoadjuvant/preoperative endocrine therapy according to menopausal status and delaying surgery  
• Discordant biopsies likely to be malignant |
| Low      | • Excision of benign lesions and duct excision (fibroadenomas, atypia, papilloma)  
• Surgery of noninvasive breast cancer (in situ), except for extended high-grade DCIS  
• Discordant biopsies likely to be benign  
• Breast reconstruction with autologous tissue and/or implants  
• Prophylactic surgery for asymptomatic high-risk patients |

*Abbreviations: DCIS, ductal carcinoma in situ; ER, estrogen receptor; HER2, human epidermal receptor 2; MDT, multidisciplinary tumor board meeting; PR, progesterone receptor.*

### Table 3 Prioritization of radiation for breast cancer based on treatment indication8

<table>
<thead>
<tr>
<th>Priority for breast RT</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| High priority for breast RT | • Inflammatory breast cancer  
• Residual node positivity after NAC  
• Four or more positive nodes (N2)  
• Recurrent disease  
• Node-positive triple-negative BC  
• Extensive LVI |
| Intermediate priority for breast RT | • ER+ with 1–3 positive nodes (N1a)  
• Pathology N0 after NAC  
• LVI (NOS)  
• Node-negative triple-negative BC |
| Low priority for breast RT | • Early-stage ER+ breast cancer (especially elderly)  
• Ductal carcinoma in situ  
• Otherwise not meeting criteria for high and intermediate priority |

*Abbreviations: BC, breast cancer; ER, estrogen receptor; LVI, lympho-vascular invasion; NAC, neoadjuvant chemotherapy; NOS, no other specified; RT, radiotherapy.*


Delay in RT treatment may be safely done for ER+ breast cancer patient for up to 5 months if they are established on endocrine therapy and have received prior chemotherapy.8,16,17

**Systemic Therapy**

The objective of systemic therapy is to ensure appropriate cancer care and to protect patients with cancer from the risk of COVID-19 infection.8

We should minimize the presence of cancer patients at the hospital. Patients should be encouraged to be managed at home by telemedicine and phone calls. Oral chemotherapy and hormonal therapy drugs should be preferred to intravenous drugs. Other alternatives such as intravenous and subcutaneous anticancer agents can be made available at home. The schedule of chemotherapy could be adjusted to decrease hospital visit, for example every 3 weeks, compared to weekly basis. Patients with slowly evolving metastatic cancer can break temporarily. All the decisions should be discussed by the MDT and shared with patients and their families.18,19

The preventive measures in hospitals should be improved. Daily phone calls to check symptoms of COVID-19 in patients, who are planned for hospital treatment in the following day, should be done regularly. Separation measures in hospital must be implemented, for example ensuring appropriate space between seats. Caregivers should not be allowed for all in- and outpatients except in selected cases, for instance for children who need continuous assistance. Surgical masks and handwashing with a hydro-alcoholic solution should be provided to all patients and staff at the hospital entrance. MDT meetings should be done in a virtual setting or internally.18,19

The criteria for patient admission to hospital for systemic therapy should depend on curative or palliative intent, patient age, and their life expectancy. The priority for patient admission to hospital for systemic therapy should be set in the following order: (1) patient with curative intent treatment, favoring those with less than or equal to 60 years or life expectancy ≥5 years; (2) cancer patients with (a) noncurative intent and less than or equal to 60 years old, (b) 5 years life expectancy or more, or (c) both and in first-line; and (3) others with noncurative care, favoring those with quickly evolving and symptomatic metastatic cancer.8

**Recommendation for Systemic Therapy**

There is still limited study related to breast cancer management during the COVID-19 pandemic. In recent weeks, there were recommendations from the cancer working groups and country experiences in handling breast cancer patients during COVID-19. For further details on the priority of systemic therapy in early and metastatic breast cancer, see Tables 5 and 6.

**Supportive Care**

Home administration of supportive care should be implemented in all cancer patients. Patients were taught to do physical and recreational activities using web-platforms. Psychological support also could be provided by phone calls or other telemedicine measures.8

Medical rehabilitation should be postponed, especially several activities like use of nebulizer, cough assist manual, cough assist measures such as flutter and acapella, and cough exercise. Some conditions can be postponed such as spinal cord injury, acute neuromuscular disease, severe pain not relieved by optimal pain killers, severe mucus retention, dysphagia, and sudden loss of body function.22

**Clinical Trial**

Participation in clinical trials should be adjusted. Patients’ accrual in ongoing trials should be limited and case-by-case accrual in trials providing new effective treatments to patients without valid standard alternatives should be discussed. On-study patients could be referred to other active centers in the case of issues due to COVID-19 reorganization. In-person visits should be replaced with telephone calls or other telemedicine visits, and also the implementation of drug shipment to patients should be ensured. Research nurses’ visits should be replaced with phone calls or other telemedicine visit measures.8,21

**Conclusion**

This review was done in the middle of COVID-19 outbreak. From the literature search results, there is still paucity of evidence regarding the management of breast cancer in COVID-19 times. Several oncology societies have released

---

**Table 4** Radiotherapy treatments that may be omitted in breast cancer13,15

<table>
<thead>
<tr>
<th>Subsite or classification</th>
<th>Modality</th>
<th>Comments and evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>* Breast conservation*</td>
<td></td>
<td>Omission of radiotherapy to the whole breast</td>
</tr>
<tr>
<td>* DCIS*</td>
<td></td>
<td>Omission of radiotherapy to the whole breast</td>
</tr>
<tr>
<td>* Invasive disease*</td>
<td></td>
<td>Omission of radiotherapy to the whole breast</td>
</tr>
<tr>
<td>* Low risk, older patients*</td>
<td></td>
<td>Omission of boost radiotherapy</td>
</tr>
<tr>
<td>* Genomic profile, low risk*</td>
<td></td>
<td>Omit radiotherapy</td>
</tr>
</tbody>
</table>

Abbreviations: DCIS, ductal carcinoma in situ; ER, estrogen receptor; HER2, human epidermal receptor 2.
guidelines about the management of breast cancer patients. The guidelines are based on experiences of experts in breast cancer field. Till present time, the COVID-19 cases have kept increasing in the world. Hence, people who are involved in breast cancer management are working together hand in hand to solve the problem and give the best for patient care.

A group of experts from various specializations is required for the optimal care of breast cancer patients. The MDTs should regularly meet up to discuss every problematic breast cancer patient, especially who got infected with COVID-19. This meeting will allow all key oncology specialists to join the discussion on individual breast cancer patient. The MDT consists of surgical, radiation, and medical oncologists together with pathologist, pharmacist, radiologist, nurses, palliative care people, and nutritionists. Several consortiums of cancer and COVID-19 registry have been formed, involving multinational oncology centers in the world. From the cancer registry, we can learn more about the management of cancer, especially breast cancer, in COVID-19 era.

Several international oncology societies have released the breast cancer recommendations during the COVID-19 pandemic but there is still questionable-quality evidence. In this difficult situation, all people who are involved in oncology field will learn together regarding cancer management in COVID-19 times.

<table>
<thead>
<tr>
<th>Table 5</th>
<th>Priorities for breast cancer: medical oncology-early breast cancer (^{20,21})</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Priority</strong></td>
<td><strong>Recommendation</strong></td>
</tr>
</tbody>
</table>
| **High** | • Neoadjuvant and adjuvant chemotherapy for triple-negative breast cancer patients  
• Neoadjuvant and adjuvant chemotherapy in combination with targeted therapy for HER2-positive breast cancer patients  
• Neoadjuvant and adjuvant endocrine therapy ± chemotherapy for high-risk ER-positive/HER2-negative breast cancer  
• Completion of neoadjuvant chemotherapy (with or without anti-HER2 therapy) that has already been initiated  
• Continuation of adjuvant capecitabine treatment in high-risk triple-negative breast cancer patients, and T-DM1 in high-risk HER2-positive breast cancer patients (in the post neoadjuvant settings)  
• Continuation of treatment in the context of a clinical trial, provided patient benefits outweigh risks, with possible adaptation of procedures without affecting patient safety and study conduct |
| **Medium** | • For postmenopausal women with stage I cancers, with low-intermediate-grade tumors, or lobular breast cancers, endocrine therapy may be started first while surgery can be delayed  
• For patients with low-risk genomic signatures/score, prefer endocrine therapy alone  
• Ongoing adjuvant trastuzumab alone may be postponed by 6–8 weeks in patients at high risk of complicated COVID-19 infection |
| **Low** | • Follow-up imaging, restaging studies, echocardiograms, ECGs, and bone density scans can be delayed if patient is clinically asymptomatic or has clinical signs of response in the neoadjuvant settings |

Abbreviations: COVID-19, Coronavirus disease 2019; ECGs, electrocardiograms; ER, estrogen receptor; HER2, human epidermal receptor 2.

<table>
<thead>
<tr>
<th>Table 6</th>
<th>Priorities for breast cancer: medical oncology-metastatic breast cancer (^{20,21})</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Priority</strong></td>
<td><strong>Recommendation</strong></td>
</tr>
</tbody>
</table>
| **High** | • Early line chemotherapy, endocrine therapy, targeted therapy agents, or immune checkpoint inhibitors likely to improve outcomes in metastatic disease (high priority to pertuzumab/trastuzumab plus chemotherapy in HER2-positive breast cancer)  
• Visceral crisis  
• Continuation of treatment in the context of a clinical trial, provided patient benefits outweigh risks, with possible adaptation of procedures without affecting patient safety and study conduct |
| **Medium** | • Second-, third-, and beyond third-line treatment when therapy may provide clinical benefit and impact on outcome  
• Consider avoiding or delaying the addition of mTOR or PIK3CA inhibitors to endocrine therapy, particularly in elderly patients with comorbidities |
| **Low** | • Bone agent therapy (zoledronic acid, denosumab) not urgently needed for hypercalcemia, or not needed for pain control and in patients who are otherwise not in need of coming to the hospital (for instance receiving oral chemotherapy or endocrine therapy); bone agents can be administered every 3 months  
• If clinically asymptomatic, follow-up imaging, restaging studies, echocardiograms, and ECGs can be delayed or done at lengthened intervals |

Abbreviations: ECGs, electrocardiograms; HER2, human epidermal receptor 2; mTOR, mammalian target of rapamycin; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.
Conflict of Interest
None declared.

Acknowledgments
The authors would like to thank their students for the support in searching and evaluating the articles.

References